Edna Mozes
240 Hertzl Street
Rehovot, M 76100, Israel
Rehovot, M 76100, Israel
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Indoleamine-2,3-dioxygenase in murine and human systemic lupus erythematosus: Down-regulation by the tolerogeneic peptide hCDR1.
Journal: Clinical immunology (Orlando, Fla.)
Published: July 10, 2018
The tolerogenic peptide hCDR1 immunomodulates cytokine and regulatory molecule gene expression in blood mononuclear cells of primary Sjogren's syndrome patients.
Journal: Clinical immunology (Orlando, Fla.)
Published: April 29, 2018
Anticitrullinated Protein Antibodies Induce Inflammatory Gene Expression Profile in Peripheral Blood Cells from CCP-positive Patients with RA.
Journal: The Journal of rheumatology
Published: September 25, 2017
Novel approaches to the development of targeted therapeutic agents for systemic lupus erythematosus.
Novel approaches to the development of targeted therapeutic agents for systemic lupus erythematosus.
Journal: Journal of autoimmunity
Published: June 02, 2014
16/6-idiotype expressing antibodies induce brain inflammation and cognitive impairment in mice: the mosaic of central nervous system involvement in lupus.
Journal: BMC medicine
Published: September 28, 2012
The tolerogenic peptide, hCDR1, down-regulates the expression of interferon-α in murine and human systemic lupus erythematosus.
Journal: PloS one
Published: September 21, 2012
A novel tolerogenic peptide, hCDR1, for the specific treatment of systemic lupus erythematosus.
Journal: Autoimmunity reviews
Published: June 30, 2010
A novel synthetic peptide for the specific treatment of lupus: clinical effects and mechanism of action.
Journal: The Israel Medical Association journal : IMAJ
Published: February 28, 2008
Showing 1-9 of 9
Last Updated: 09/26/2026